TBCRC 008: Early Change in (18)F-FDG Uptake on PET Predicts Response to Preoperative Systemic Therapy in Human Epidermal Growth Factor Receptor 2–Negative Primary Operable Breast Cancer

Epigenetic modifiers, including the histone deacetylase inhibitor vorinostat, may sensitize tumors to chemotherapy and enhance outcomes. We conducted a multicenter randomized phase II neo-adjuvant trial of carboplatin and nanoparticle albumin-bound paclitaxel (CP) with vorinostat or placebo in women...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Nucl Med
Autori principali: Connolly, Roisin M., Leal, Jeffrey P., Goetz, Matthew P., Zhang, Zhe, Zhou, Xian C., Jacobs, Lisa K., Mhlanga, Joyce, Joo, H O, Carpenter, John, Storniolo, Anna Maria, Watkins, Stanley, Fetting, John H., Miller, Robert S., Sideras, Kostandinos, Jeter, Stacie C., Walsh, Bridget, Powers, Penny, Zorzi, Jane, Boughey, Judy C., Davidson, Nancy E., Carey, Lisa A., Wolff, Antonio C., Khouri, Nagi, Gabrielson, Edward, Wahl, Richard L., Stearns, Vered
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2014
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4352313/
https://ncbi.nlm.nih.gov/pubmed/25476537
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2967/jnumed.114.144741
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi